ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 998,02
0,06%
Dow Jones
38 279,72
-1,05%
DAX
18 608,16
0,68%
Brent Oil
78,29
-3,11%
Bitcoin
69 052,22
1,93%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Legend Biotech Corporation (LEGN)

  7. Legend Biotech Corporation (LEGN) Actualités

LEGN

Legend Biotech (LEGN)

Legend Biotech Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:LEGN
DateHeureSourceTitreSymboleSociété
29/05/202414h00Business WireLegend Biotech to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:LEGNLegend Biotech Corporation
23/05/202423h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
23/05/202423h00Business WireLegend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHANASDAQ:LEGNLegend Biotech Corporation
13/05/202413h10IH Market NewsU.S. Futures Climb Amid High Expectations for Inflation Data; Global Markets Show Mixed ReactionsNASDAQ:LEGNLegend Biotech Corporation
13/05/202413h00Business WireLegend Biotech Reports First Quarter 2024 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
22/04/202419h05Business WireCARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
11/04/202414h00Business WireLegend Biotech to Host Investor Conference Call on First Quarter 2024 ResultsNASDAQ:LEGNLegend Biotech Corporation
06/04/202405h30Business WireLegend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
19/03/202413h30Business WireLegend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) ReportNASDAQ:LEGNLegend Biotech Corporation
15/03/202420h15Business WireCARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
11/03/202412h00Business WireLegend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
11/03/202411h39IH Market NewsU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge HigherNASDAQ:LEGNLegend Biotech Corporation
29/02/202400h46Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:LEGNLegend Biotech Corporation
28/02/202401h47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
23/02/202413h15Business WireLegend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of TherapyNASDAQ:LEGNLegend Biotech Corporation
15/02/202402h34Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LEGNLegend Biotech Corporation
13/02/202414h00Business WireLegend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 ResultsNASDAQ:LEGNLegend Biotech Corporation
03/01/202417h28Business WireLegend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3NASDAQ:LEGNLegend Biotech Corporation
02/01/202414h30Business WireLegend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:LEGNLegend Biotech Corporation
12/12/202301h30Business WirePatient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)NASDAQ:LEGNLegend Biotech Corporation
20/11/202312h25IH Market NewsMonday’s Wall Street Highlights: GM, Microsoft, Citigroup, Amazon, and moreNASDAQ:LEGNLegend Biotech Corporation
20/11/202312h00Business WireLegend Biotech Reports Third Quarter 2023 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
13/11/202315h16Dow Jones NewsLegend Biotech Subsidiary in License Agreement With NovartisNASDAQ:LEGNLegend Biotech Corporation
13/11/202314h30Business WireLegend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3NASDAQ:LEGNLegend Biotech Corporation
07/11/202314h30Business WireLegend Biotech to Host Investor Conference Call on Third-Quarter ResultsNASDAQ:LEGNLegend Biotech Corporation
02/11/202314h17Business WireLegend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual MeetingNASDAQ:LEGNLegend Biotech Corporation
15/08/202312h00Business WireLegend Biotech Reports Second Quarter 2023 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
03/08/202314h30Business WireLegend Biotech to Host Investor Conference Call on Second-Quarter ResultsNASDAQ:LEGNLegend Biotech Corporation
26/06/202316h31Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:LEGNLegend Biotech Corporation
06/06/202322h30Business WireLegend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)NASDAQ:LEGNLegend Biotech Corporation
 Showing the most relevant articles for your search:NASDAQ:LEGN

Dernières Valeurs Consultées

TSXV
GID
BIT
P13ZR7
BNP Paribas Issuance
BIT
P1TZ34
BNP Paribas Issuance
TSXV
OCA.P
LSE
BR31
Citi Fun 28
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés